Inhibition of METTL3 not only promotes the immune response and enhances the immunogenicity of tumour cells, but also reverses T‐cell exhaustion in tumour microenvironment, thereby sensitising ICB‐based immunotherapy. The gene discussed is METTL3; the disease is neoplasm.